Quantitative assessment of myocardial perfusion abnormality on SPECT myocardial perfusion imaging is more reproducible than expert visual analysis
- PMID: 19152128
- PMCID: PMC3569514
- DOI: 10.1007/s12350-008-9018-0
Quantitative assessment of myocardial perfusion abnormality on SPECT myocardial perfusion imaging is more reproducible than expert visual analysis
Abstract
Background: Current guidelines of Food and Drug Administration for the evaluation of SPECT myocardial perfusion imaging (MPI) in clinical trials recommend independent visual interpretation by multiple experts. Few studies have addressed whether quantitative SPECT MPI assessment would be more reproducible for this application.
Methods and results: We studied 31 patients (age 68 +/- 13, 25 male) with abnormal stress MPI who underwent repeat exercise (n = 11) or adenosine (n = 20) MPI within 9-22 months (mean 14.9 +/- 3.8 months) and had no interval revascularization or myocardial infarction and no change in symptoms, stress type, rest or stress ECG, or clinical response to stress on the second study. Visual interpretation per FDA Guidance used 17-segment, 5-point scoring by two independent expert readers with overread of discordance by a third expert, and percent myocardium abnormal was derived from normalized summed scores. The quantitative magnitude of perfusion abnormality was assessed by the total perfusion deficit (TPD), expressing stress, rest, and ischemic perfusion abnormality. High linear correlations were observed between visual and quantitative size of stress, rest, and ischemic defects (R = 0.94, 0.92, 0.84). Correlations of two tests were higher by quantitative than by visual methods for stress (R = 0.97 vs R = 0.91, P = 0.03) and rest defects (R = 0.94 vs R = 0.82, P = 0.03), respectively, and statistically similar for ischemic defects (R = 0.84 vs R = 0.70, P = ns).
Conclusions: In stable patients having serial SPECT MPI, quantification is more reproducible than visual for magnitude of perfusion abnormality, suggesting its superiority for use in randomized clinical trials and monitoring the effects of therapy in an individual patient.
Figures







Comment in
-
Automated assessment of serial SPECT myocardial perfusion images.J Nucl Cardiol. 2009 Jan-Feb;16(1):6-9. doi: 10.1007/s12350-008-9020-6. Epub 2009 Jan 20. J Nucl Cardiol. 2009. PMID: 19152123 No abstract available.
Similar articles
-
Automated assessment of serial SPECT myocardial perfusion images.J Nucl Cardiol. 2009 Jan-Feb;16(1):6-9. doi: 10.1007/s12350-008-9020-6. Epub 2009 Jan 20. J Nucl Cardiol. 2009. PMID: 19152123 No abstract available.
-
Validation of an automated method to quantify stress-induced ischemia and infarction in rest-stress myocardial perfusion SPECT.J Nucl Cardiol. 2014 Jun;21(3):503-18. doi: 10.1007/s12350-014-9863-y. Epub 2014 Feb 15. J Nucl Cardiol. 2014. PMID: 24532031 Clinical Trial.
-
Comparison of the extent and severity of myocardial perfusion defects measured by CT coronary angiography and SPECT myocardial perfusion imaging.JACC Cardiovasc Imaging. 2010 Oct;3(10):1010-9. doi: 10.1016/j.jcmg.2010.07.011. JACC Cardiovasc Imaging. 2010. PMID: 20947046
-
Serial myocardial perfusion imaging: defining a significant change and targeting management decisions.JACC Cardiovasc Imaging. 2014 Jan;7(1):79-96. doi: 10.1016/j.jcmg.2013.05.022. JACC Cardiovasc Imaging. 2014. PMID: 24433711 Review.
-
Artifacts in Quantitative analysis of myocardial perfusion SPECT, using Cedars-Sinai QPS Software.J Nucl Cardiol. 2017 Apr;24(2):534-542. doi: 10.1007/s12350-016-0726-6. Epub 2016 Nov 10. J Nucl Cardiol. 2017. PMID: 27834038 Review.
Cited by
-
Tracking a therapeutic response: how reliable are serial measurements of LV perfusion and function?J Nucl Cardiol. 2012 Apr;19(2):360-3. doi: 10.1007/s12350-012-9518-9. J Nucl Cardiol. 2012. PMID: 22297852 Free PMC article. Review. No abstract available.
-
ISCHEMIA: A Search for clarity and why we may not find it.Am Heart J. 2018 Sep;203:82-84. doi: 10.1016/j.ahj.2018.03.031. Epub 2018 Jun 20. Am Heart J. 2018. PMID: 30048826 Free PMC article. No abstract available.
-
Transient ischaemic dilation and post-stress wall motion abnormality increase risk in patients with less than moderate ischaemia: analysis of the REFINE SPECT registry.Eur Heart J Cardiovasc Imaging. 2020 May 1;21(5):567-575. doi: 10.1093/ehjci/jez172. Eur Heart J Cardiovasc Imaging. 2020. PMID: 31302679 Free PMC article.
-
Prognostic value of quantitative high-speed myocardial perfusion imaging.J Nucl Cardiol. 2012 Dec;19(6):1113-23. doi: 10.1007/s12350-012-9619-5. Epub 2012 Oct 12. J Nucl Cardiol. 2012. PMID: 23065414 Free PMC article.
-
Quantitative myocardial perfusion imaging by cardiovascular magnetic resonance and positron emission tomography.J Nucl Cardiol. 2013 Oct;20(5):860-70; quiz 857-9, 871-3. doi: 10.1007/s12350-013-9762-7. Epub 2013 Jul 19. J Nucl Cardiol. 2013. PMID: 23868071 Free PMC article. Review.
References
-
- Mahmarian JJ, Shaw LJ, Filipchuk NG, et al. A multinational study to establish the value of early adenosine technetium-99m sestamibi myocardial perfusion imaging in identifying a low-risk group for early hospital discharge after acute myocardial infarction. J Am Coll Cardiol. 2006;48:2448–57. - PubMed
-
- Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–91. - PubMed
-
- Dangas G, Stone GW, Weinberg MD, et al. Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: Comparison with primary angioplasty and the role of distal protection devices (EMERALD trial) Am Heart J. 2008;155:1090–6. - PubMed
-
- Schwartz RG, Pearson TA, Kalaria VG, et al. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of pravastatin therapy: Coronary artery disease regression single photon emission computed tomography monitoring trial. J Am Coll Cardiol. 2003;42:600–10. - PubMed
-
- U.S. Department of Health and Human Services, FDA. Guidance for industry developing medical imaging drug and biological products. Part 3: Design, analysis, and interpretation of clinical studies. 2004 Jun; http://www.fda.gov/cber/gdlns/medimagestud.htm.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous